About Inpharmatica
Inpharmatica is a company based in London (United Kingdom) founded in 1998 was acquired by Galapagos in December 2006. The company has 62 employees as of January 31, 2021. Inpharmatica offers products and services including Chemogenomics, Druggability, and Silico. Inpharmatica operates in a competitive market with competitors including Insitro, Helix, Benchling, HotSpot Therapeutics and TOLREMO therapeutics, among others.
- Headquarter London, United Kingdom
- Employees 62 as on 31 Jan, 2021
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Galapagos Biotech Limited
- Date of Incorporation 08 Jul, 1997
- Jurisdiction CAMBRIDGE, CAMBRIDGESHIRE
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Inpharmatica
Inpharmatica offers a comprehensive portfolio of products and services, including Chemogenomics, Druggability, and Silico.
Proprietary approach for identifying drug targets and libraries.
Assesses targets for lead chemistry potential in drug discovery.
Tools for early compound selection and property balancing.
Funding Insights of Inpharmatica
Investors in Inpharmatica
Inpharmatica has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include GLPG, 3i Group and Gimv.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early to late-stage tech investments are made globally by REV.
|
Locked | Locked | Locked | |
|
Early stage venture capital firm investing in US
|
Locked | Locked | Locked | |
|
Private equity firm focused on mid-market businesses
|
Locked | Locked | Locked |
Investor details for Inpharmatica
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Inpharmatica
Investment portfolio details for Inpharmatica
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Inpharmatica
Detailed financials for Inpharmatica
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Inpharmatica Comparisons
Peer comparison for Inpharmatica
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Inpharmatica
Inpharmatica operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, Helix, Benchling, HotSpot Therapeutics and TOLREMO therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Genomic database for clinical research is provided.
|
|
| Locked | Locked | Locked |
Cloud-based bioinformatics platform is offered for biotech research.
|
|
| Locked | Locked | Locked |
Developer of a platform for protein function analysis
|
|
| Locked | Locked | Locked |
Anti-cancer small molecules are developed to target drug resistance pathways.
|
|
| Locked | Locked | Locked |
Provider of a platform for in silico drug discovery and consulting services
|
Detailed competitors of Inpharmatica
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Inpharmatica
Complete news archive for Inpharmatica
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Inpharmatica
Inpharmatica was founded in 1998.
Inpharmatica is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
John Lisle is the current CEO of Inpharmatica.
As of Jan 31, 2021, the latest employee count at Inpharmatica is 62.
Inpharmatica has developed a platform that uses predictive informatics in medicinal chemistry and ADME for drug discovery. The Chemagenomics platform is used for in silico target selection through drug assessment and identification of leads. The company also offers another platform called Silico used for ADME optimization, in silicon and in vitro assessments for identifying leads from hits.
Inpharmatica's top competitors include Insitro, Helix and HotSpot Therapeutics.
Inpharmatica offers Chemogenomics, Druggability, and Silico.
Inpharmatica has 8 investors. Key investors include GLPG, 3i Group, Gimv, Abingworth, and REV.